The new drug pricing system in 2025 is expected to be volatile due to Korea’s political turmoil. Whether the external reference pricing reevaluations and re-evaluation of the listed PE exemption drugs, which were reviewed or discussed last year, will be carried out this year is also the focus of attention.

However, as most of the detailed measures for 'Reflecting the Innovative Value of New Drugs and Improving the Drug Pricing System for Health Security' have been revised, the revisions are expected to be implemented in earnest this year. In particular, the partial revision of the 'Criteria for the Determination and Adjustment of Drugs (administrative notice issued in October 2024), which cont